✦ LIBER ✦

Intra-arterial epirubicin/cisplatin + oral capecitabine in biliary cancer

Book ID: 120845877
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2007
Weight: 133 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200716010-00045

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

3550 POSTER Capecitabine plus hepatic in

3550 POSTER Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study

✍ P. Pacetti; A. Mambrini; A. Guglielmi; C. Iacono; T. Torri; M. Orlandi; S. Guada 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

A randomised phase II study of combinati

A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer

✍ Jina Yun; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 180 KB

PCN37 PRELIMINARY COST-CONSEQUENCE ANALY

PCN37 PRELIMINARY COST-CONSEQUENCE ANALYSIS OF EPIRUBICIN/CISPLATIN/5FU (ECF) COMPARED TO EPIRUBICIN/CISPLATIN/CAPECITABINE (ECX) IN PATIENTS WITH ADVANCED OESOPHAGOGASTRIC CANCER

✍ AM Horgan; J Knox; G Liu; PA Bradbury; C Sahi; NB Leighl 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Phase II study of capecitabine and cispl

Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer

✍ Yong Sang Hong; Jeeyun Lee; Sang Cheol Lee; In Gyu Hwang; Seong-Ho Choi; Jin-Seo 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 391 KB

6639 POSTER Polymorphisms Associated Wit

6639 POSTER Polymorphisms Associated With the Clinical Outcome of Biliary Tract Cancer (BTC) Patients Treated With the Epirubicin, Cisplatin and Capecitabine (ECX) Regimen

✍ Pacetti, P.; Giovannetti, E.; Mambrini, A.; Zaccarelli, E.; Orlandi, M.; Alecci, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Induction intra-arterial cisplatin and b

Induction intra-arterial cisplatin and bleomycin in head and neck cancer

✍ Dr. Sergio Frustaci; Luigi Barzan; Giuseppe Caruso; Riccardo Ghirardo; Silva Fol 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 658 KB

Fifty-two consecutive patients, affected by large T2 (>3 cm), T3, T4, NO, or N1 previously untreated squamous cell carcinoma of the head and neck, entered this phase 1-11 study. Treatment consisted of a continuous 8-day infusion on the following daily schedule: cisplatin 25 mg and bleomycin 15 rng a